Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. (HBIO) on April 28, 2022, covering events occurring on April 27 and April 28, 2022. The filing addresses the resolution of a long-standing wrongful death lawsuit and a concurrent amendment to the Company's credit facilities.
Key Financial Metrics and Material Changes
The filing does not provide standard periodic financial metrics such as revenue, profit, cash flow, or margins. The primary financial disclosures relate to litigation costs and debt covenant modifications:
- Litigation Costs: The Company anticipates total costs of approximately $6 million related to the settlement. Of this amount, approximately $4 million is expected to be paid by the Company by the end of the second quarter of 2022.
- Indemnification: The costs are to be indemnified by Biostage, Inc., a former subsidiary spun off in 2013. Biostage is expected to issue senior convertible preferred stock to satisfy $4 million of the indemnification obligation.
- Debt Covenant Modification: The Company amended its Credit Agreement (dated December 22, 2020) to modify the financial covenant relating to the consolidated net leverage ratio and to obtain lender consent for the settlement terms.
Guidance, Outlook, Risks, and Contingencies
Settlement Terms: The settlement resolves all claims regarding a wrongful death complaint filed in 2017 involving products used in Europe in 2012 and 2013. Neither the Company nor Biostage admitted liability or fault. The claims will be dismissed with prejudice.
Recovery Uncertainty: Management notes significant uncertainty regarding the recovery of costs. Due to Biostage's current financial condition, there is no assurance that the indemnification obligation or the value of the convertible preferred stock will offset the amounts incurred by the Company.
Forward-Looking Statements: The report includes standard disclaimers regarding risks and uncertainties that could cause actual results to differ from expectations, referencing the Annual Report on Form 10-K for the year ended December 31, 2021, for a detailed discussion of risks.
Investor Verification Checklist
- Verify the definitive terms of the senior convertible preferred stock issuance from Biostage to Harvard Bioscience.
- Assess the financial stability of Biostage, Inc. to determine the likelihood of full indemnification recovery.
- Review the specific modifications to the consolidated net leverage ratio covenant in the amended Credit Agreement (Exhibit 10.1).
- Monitor the timing and actual amount of the $4 million payment expected in the second quarter of 2022.